

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 56432

Title: Management of pembrolizumab-induced steroid refractory mucositis with Infliximab – A Case Report

Reviewer's code: 05207865

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: Brazil

Author's Country/Territory: United States

Manuscript submission date: 2020-05-23

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-05-25 14:50

Reviewer performed review: 2020-06-10 16:44

Review time: 16 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgooffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

The title reflects the main subject of the manuscript and is very direct on the theme. The summary is adequate. It is a case report that is well described, with a good review of the literature and relevance in the aspect of originality. As the situation reported is rare, there is a fundamental interest in publicizing this result. The manuscript interprets the findings appropriately and appropriately, highlighting the main points in a concise, clear and logical manner. The figures are of good quality and adequately illustrate the content of the paper. The manuscript met the ethics requirements.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 56432

Title: Management of pembrolizumab-induced steroid refractory mucositis with
Infliximab – A Case Report

Reviewer's code: 05207865

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: Brazil

Author's Country/Territory: United States

Manuscript submission date: 2020-05-23

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2020-07-27 11:38

Reviewer performed review: 2020-07-31 17:57

Review time: 4 Days and 6 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The authors reviewed and corrected the nonconformities pointed out. The study is a case report, and as such, it has the characteristics of being concise and direct, presenting a rare case of mucositis after using Pembrolizumab.